Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y
Signal Transduct Target Ther. 2025; 10(1):93.
PMID: 40055311
PMC: 11889221.
DOI: 10.1038/s41392-025-02124-y.
Yoshino O, Ono Y
Reprod Med Biol. 2025; 24(1):e12637.
PMID: 39959577
PMC: 11827100.
DOI: 10.1002/rmb2.12637.
Li R, Huang J, Wei Y, Wang Y, Lu C, Liu J
Int J Nanomedicine. 2024; 19:13615-13651.
PMID: 39717515
PMC: 11665441.
DOI: 10.2147/IJN.S491573.
Wei Y, Li R, Wang Y, Fu J, Liu J, Ma X
Int J Nanomedicine. 2024; 19:10129-10144.
PMID: 39381025
PMC: 11460276.
DOI: 10.2147/IJN.S466315.
Toledo B, Zhu Chen L, Paniagua-Sancho M, Marchal J, Peran M, Giovannetti E
J Hematol Oncol. 2024; 17(1):44.
PMID: 38863020
PMC: 11167803.
DOI: 10.1186/s13045-024-01559-0.
Targeting tumor‑associated macrophages: Critical players in tumor progression and therapeutic strategies (Review).
Su P, Li O, Ke K, Jiang Z, Wu J, Wang Y
Int J Oncol. 2024; 64(6).
PMID: 38695252
PMC: 11087038.
DOI: 10.3892/ijo.2024.5648.
Targeting tumor-associated macrophages: Novel insights into immunotherapy of skin cancer.
Liu J, Lu J, Wu L, Zhang T, Wu J, Li L
J Adv Res. 2024; 67():231-252.
PMID: 38242529
PMC: 11725115.
DOI: 10.1016/j.jare.2024.01.013.
Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms.
Zheng J, Jiang J, Pu Y, Xu T, Sun J, Zhang Q
Front Bioeng Biotechnol. 2023; 11:1248421.
PMID: 37654704
PMC: 10466823.
DOI: 10.3389/fbioe.2023.1248421.
Cellular senescence primes liver fibrosis regression through Notch-EZH2.
Song P, Duan J, Ding J, Liu J, Fang Z, Xu H
MedComm (2020). 2023; 4(5):e346.
PMID: 37614965
PMC: 10442476.
DOI: 10.1002/mco2.346.
Exploring association of melanoma-specific Bcl-xL with tumor immune microenvironment.
Luciano A, Di Martile M, Perez-Oliva A, Di Caprio M, Foddai M, Buglioni S
J Exp Clin Cancer Res. 2023; 42(1):178.
PMID: 37488586
PMC: 10364435.
DOI: 10.1186/s13046-023-02735-9.
Harnessing anti-tumor and tumor-tropism functions of macrophages via nanotechnology for tumor immunotherapy.
Zheng Y, Han Y, Sun Q, Li Z
Exploration (Beijing). 2023; 2(3):20210166.
PMID: 37323705
PMC: 10190945.
DOI: 10.1002/EXP.20210166.
Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy.
Ullah Khan S, Khan M, Azhar Ud Din M, Khan I, Khan M, Bungau S
Front Immunol. 2023; 14:1166487.
PMID: 37138860
PMC: 10149956.
DOI: 10.3389/fimmu.2023.1166487.
[Melanoma-associated macrophages-from molecular signals to therapeutic application].
Chatziioannou E, Aydin S, Forchhammer S, Sinnberg T, Eigentler T
Dermatologie (Heidelb). 2022; 73(12):915-928.
PMID: 36394590
DOI: 10.1007/s00105-022-05077-3.
The role of tumor-associated macrophages and soluble mediators in pulmonary metastatic melanoma.
Xiong K, Qi M, Stoeger T, Zhang J, Chen S
Front Immunol. 2022; 13:1000927.
PMID: 36131942
PMC: 9483911.
DOI: 10.3389/fimmu.2022.1000927.
The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease.
Ma S, Zhang J, Liu H, Li S, Wang Q
Front Cell Dev Biol. 2022; 10:896591.
PMID: 35721513
PMC: 9199005.
DOI: 10.3389/fcell.2022.896591.
Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy.
Schweer D, McAtee A, Neupane K, Richards C, Ueland F, Kolesar J
Cancers (Basel). 2022; 14(9).
PMID: 35565348
PMC: 9101750.
DOI: 10.3390/cancers14092220.
Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
Glass E, Hoover A, Bullock K, Madden M, Reinfeld B, Harris W
BMC Cancer. 2022; 22(1):497.
PMID: 35513776
PMC: 9074180.
DOI: 10.1186/s12885-022-09612-2.
Targeted Drug Delivery for the Treatment of Blood Cancers.
Jiang Y, Lin W, Zhu L
Molecules. 2022; 27(4).
PMID: 35209102
PMC: 8880555.
DOI: 10.3390/molecules27041310.
Macrophage-Mediated Melanoma Reduction after HP-NAP Treatment in a Zebrafish Xenograft Model.
Codolo G, Facchinello N, Papa N, Bertocco A, Coletta S, Benna C
Int J Mol Sci. 2022; 23(3).
PMID: 35163566
PMC: 8836027.
DOI: 10.3390/ijms23031644.
Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting.
Hourani T, Holden J, Li W, Lenzo J, Hadjigol S, OBrien-Simpson N
Front Oncol. 2022; 11:788365.
PMID: 34988021
PMC: 8722774.
DOI: 10.3389/fonc.2021.788365.
